Clone:
REA624
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC
Alternative names:
C-C chemokine receptor type 2, C-C CKR-2, CC-CKR-2, CCR-2, Monocyte chemoattractant protein 1 receptor, MCP-1-R, MCP-1R

Extended validation for CD192 (CCR2) Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA624
REA264++
K03602++
48607++
Cells were incubated with an excess of purified unconjugated CD192 (CCR2) (REA624) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD192 (CCR2). Human peripheral blood mononuclear cells (PBMCs) were stained with CD192 (CCR2) antibodies and with a suitable counterstaining. As a control, CD192 (CCR2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD192 (CCR2) (REA624). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD192 (CCR2) (REA624). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD192 (CCR2) (REA624). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD192 (CCR2) Antibody, anti-human, REAfinity™

Overview

Clone REA624 recognizes the CD192 antigen, a G protein–linked seven transmembrane receptor, which is also known as C-C chemokine receptor type 2 (CCR2) or monocyte chemoattractant protein 1 receptor (MCP-1-R). Two spliced variants of CD192 (CD192A and CD192B) are expressed on peripheral monocytes and basophils as a result of alternate splicing of a single gene and differ at the C-terminal end. CD192 and its main ligand CCL2 have been implicated in a wide range of immunobiological processes and neuropathologies, including recruitment of monocytes and regulation of bone marrow homeostasis, as well as multiple sclerosis, HIV-associated dementia, Alzheimer’s disease, and neuropathic pain.
Additional information: Clone REA624 displays negligible binding to Fc receptors.

Alternative names

C-C chemokine receptor type 2, C-C CKR-2, CC-CKR-2, CCR-2, Monocyte chemoattractant protein 1 receptor, MCP-1-R, MCP-1R

Detailed product information

Technical specifications

CloneREA624
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD192 (CCR2)
Alternative names of antigenC-C chemokine receptor type 2, C-C CKR-2, CC-CKR-2, CCR-2, Monocyte chemoattractant protein 1 receptor, MCP-1-R, MCP-1R
Molecular mass of antigen [kDa]42
Distribution of antigenmonocytes, basophils
Entrez Gene ID1231
RRIDAB_2655866, AB_2655867, AB_2655868, AB_2655869, AB_2655870, AB_2655871, AB_2655872, AB_2655873, AB_2655874, AB_2655875

References for CD192 (CCR2) Antibody, anti-human, REAfinity™

Publications

  1. Charo, I. F. et al. (1994) Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. U.S.A. 91(7): 2752-2756
  2. Wong, L. M. et al. (1997) Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J. Biol. Chem. 272(2): 1038-1045
  3. Henrich, T. J. et al. (2013) HIV-1 entry inhibitors: recent development and clinical use. Curr. Opin. Virol. 3(1): 51-57

Related products for
CD192 (CCR2) Antibody, anti-human, REAfinity™

3 products available